Central-line associated bloodstream infections (CLABSI) pose a immediate danger to vulnerable patents, infection prevention guidance is imperative for assisting acute care hospitals in prioritizing prevention efforts.  Approximately 41,000 cases of CLABSI occur in U.S. hospitals annually, increasing length of stay